Last updated 2026-07-27
- Went public on TASE (BRIN), Jan 2007
- Raised $8.5M Series C led by Noked Capital, Dec 2017
- Raised $11.8M PIPE led by Yelin Lapidot Investment House, Feb 2014
Total raised
$33.5M
Last: Debt Financing 2026-03
Stage
Public
Founded
2003
Headcount
141
HQ
Jerusalem, Israel
Sector
Health Tech & Life Sciences
About
BrainsWay is a global medical technology company focused on developing cutting-edge medical devices that help advance the field of mental healthcare. Its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology is used for the non-invasive treatment of major depressive disorder (including reduction of anxiety symptoms), obsessive-compulsive disorder (OCD), and smoking addiction. The company's technology is based on patents filed by the U.S. National Institutes of Health (NIH) and by the company, holding an exclusive license from the NIH for the patent and its technology. BrainsWay's Deep TMS system has received FDA clearance for these indications and CE Mark clearance outside of North America for numerous additional psychiatric and neurological conditions.
Funding history · 7 rounds · $33.5M total
2025-05
Follow-on PO
Undisclosed
2021-02
Follow-on PO
Undisclosed
2019-04
Follow-on PO
Undisclosed
2017-12
C Round
$8.5M
★ Noked Capital★ Phoenix Insurance★ IBI Investment House
2014-02
PIPE
$11.8M
★ Yelin Lapidot Investment House
2012-03
PIPE
$4.3M
★ Shavit Capital Fund
2007-01
Follow-on PO
$8.9M
Headcount over time
From 78 (2018-07) to 140 (2026-03) · +62 (+79%) · 59 points · source: Finder history + radar grounding
Q&A
- What was BrainsWay's most recent funding event?
- BrainsWay completed a Public Offering in May 2025.
- When did BrainsWay last raise debt financing, and for what amount?
- BrainsWay's last debt financing occurred in March 2026, raising $6,000,000.
- What is BrainsWay's current employee count?
- BrainsWay has 51-200 employees.
- What was the total amount of funding BrainsWay has raised to date?
- BrainsWay has raised a total of $89,367,000.
- When did BrainsWay receive FDA clearance for its Deep TMS 360™ System for Alcohol Use Disorder?
- BrainsWay launched its first clinical trial for the Deep TMS 360™ System for Alcohol Use Disorder in November 2025, but the data does not specify an FDA clearance date for this indication.
- What was a significant operational highlight for BrainsWay in the first quarter of 2025?
- BrainsWay reported its first quarter 2025 financial results and operational highlights in May 2025.
- Has BrainsWay made any recent strategic investments?
- In May 2026, BrainsWay announced a minority-stake investment in Hopemark Health.
- What was a key development for BrainsWay in September 2025 regarding its Deep TMS protocol?
- In September 2025, BrainsWay received FDA clearance for an accelerated Deep TMS protocol for the non-invasive treatment of Major Depressive Disorder (MDD).
- What was a notable achievement for BrainsWay in November 2025 concerning adolescent depression treatment?
- In November 2025, BrainsWay received FDA clearance of Deep TMS™ as an adjunct therapy for Major Depressive Disorder (MDD) in adolescents aged 15 to 21.
Team · 9
Avner Hagai
Founder · Co-founder
David Zacut
Founder · Co-founder
Uzi Sofer
Founder · Co-founder
Yiftach Roth
Founder · Co-founder
Abraham Zangen
Founder · Co-founder
VP R&D
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesMedical DevicesMedical Treatment & Therapeutics
Target customers
Healthcare & Life SciencesHealthcareProvidersPatients
Business model
B2B
Highlights
1 Patents
Tags
neuro-stimulationchronic-painnon-invasivepsychiatryneurologymental-healthmedical-devicesparkinsonalzheimers-diseasebrain-disorderhospitalsclinicshealthcare-providersmedical-technologiestreatmentspatients
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | brainsway.com |
|---|---|
| linkedin.com/company/3253269 | |
| facebook.com/BrainswayDeepTMS | |
| YouTube | youtube.com/channel/UCGcpxh6bCwWr76SCItRpyvw |
| instagram.com/brainsway | |
| Wikipedia | en.wikipedia.org/wiki/Brainsway |
| Wikidata | wikidata.org/wiki/Q2913953 |
Identifiers & details
| Legal name | BrainsWay Ltd. |
|---|---|
| Founded | 2003 |
| Employees (exact) | 141 |
| Offices | Burlington |
| Market cap | $372.4M |
| Status reason | Public on TASE on Jan, 2007; Public on NASDAQ on Apr, 2019 |
| Wikidata QID | Q2913953 |
Acquisitions & public offerings
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| IPO | 2007-01 | TASE | BRIN | $9.3M |
| IPO | 2019-04 | NASDAQ | BWAY | $27.5M |
Radar intelligence
Patents
| EPO | 19 |
|---|
Publications (Crossref)
| Works | 10 |
|---|
Web history (Wayback)
| Domain | brainsway.com |
|---|
Wikidata
| QID | Q2913953 |
|---|
Certificate / subdomain footprint
| Subdomains | 32 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 513890764 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה ציבורית |
| Incorporated | 2006-11-07 |
| Purpose | לעסוק בסוגי עיסוק שפורטו בתקנון |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Active charges / liens | 0 |
| Registry events | 1 — violation (1) |
| Registered address | הרטום 16 ירושלים |
Recent registry events
| Date | Event |
|---|---|
| 2026-06-01 | עדכון הפרה |